Summary:
The study drug being tested, AR1001, consists of an oral medication that is taken once a day. AR1001 is designed to improve brain cell growth and increase blood flow in the brain, while reducing toxic proteins that cause dementia and Alzheimer’s disease . This could help brain cells communicate and prevent damage caused by Alzheimer’s disease. It has shown to have an excellent safety profile.
You will be randomly assigned to receive either the study drug or a placebo (looks like the study drug but has no active ingredients). You have a 50% chance of receiving the study drug during the first 52 weeks (year 1), followed by active medication for 104 weeks (year 2 and 3).
Criteria:
Male or female participants aged 55 to 80 years of age
mild cognitive impairment or mild dementia consistent with Alzheimer's disease
Willing to receive a lumbar puncture
Have one identified adult study partner who can attend a few study visits
Qualified Participants May Receive:
$75 per visit, free visits, free medication